Leerink Swann initiated coverage on shares of Clovis Oncology (NASDAQ:CLVS) in a report released on Monday morning, MarketBeat Ratings reports. The firm issued a market perform rating and a $30.00 target price on the biopharmaceutical company’s stock. Leerink Swann also issued estimates for Clovis Oncology’s Q3 2018 earnings at ($1.52) EPS, Q4 2018 earnings at ($1.51) EPS, FY2018 earnings at ($6.51) EPS, FY2019 earnings at ($4.77) EPS, FY2020 earnings at ($1.50) EPS, FY2021 earnings at $1.10 EPS and FY2022 earnings at $2.65 EPS.
Several other brokerages have also recently commented on CLVS. Royal Bank of Canada reiterated a buy rating and issued a $73.00 price objective on shares of Clovis Oncology in a research note on Tuesday, June 12th. ValuEngine upgraded shares of Clovis Oncology from a strong sell rating to a sell rating in a report on Friday, June 1st. Cann restated a hold rating on shares of Clovis Oncology in a report on Monday, June 11th. BidaskClub downgraded shares of Clovis Oncology from a sell rating to a strong sell rating in a report on Friday, June 8th. Finally, Zacks Investment Research downgraded shares of Clovis Oncology from a hold rating to a sell rating in a report on Tuesday, July 10th. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. Clovis Oncology presently has an average rating of Hold and a consensus target price of $73.41.
Shares of NASDAQ CLVS opened at $29.69 on Monday. The company has a quick ratio of 9.21, a current ratio of 10.03 and a debt-to-equity ratio of 1.84. Clovis Oncology has a 52 week low of $29.52 and a 52 week high of $86.26. The stock has a market capitalization of $1.65 billion, a P/E ratio of -5.80 and a beta of 1.01.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.56). Clovis Oncology had a negative net margin of 382.83% and a negative return on equity of 94.28%. The company had revenue of $23.76 million during the quarter, compared to analyst estimates of $22.44 million. During the same quarter last year, the business earned ($1.29) EPS. The firm’s revenue for the quarter was up 62.5% on a year-over-year basis. research analysts anticipate that Clovis Oncology will post -6.8 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of CLVS. Ladenburg Thalmann Financial Services Inc. increased its holdings in Clovis Oncology by 5,000.0% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,550 shares of the biopharmaceutical company’s stock valued at $135,000 after acquiring an additional 2,500 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Clovis Oncology during the first quarter worth about $146,000. Advisors Asset Management Inc. grew its holdings in shares of Clovis Oncology by 1,017.5% during the second quarter. Advisors Asset Management Inc. now owns 56,668 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 51,597 shares in the last quarter. Summit Trail Advisors LLC grew its holdings in shares of Clovis Oncology by 4,092.7% during the first quarter. Summit Trail Advisors LLC now owns 249,258 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 243,313 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in shares of Clovis Oncology by 66.6% during the first quarter. LPL Financial LLC now owns 5,461 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 2,184 shares in the last quarter.
About Clovis Oncology
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Featured Article: How to calculate the intrinsic value of a stock
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.